company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-21657000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-21657000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,453000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,2922000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,8592000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,3107000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-6583000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-6583000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-325000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,netcashfromcontinuinginvestingactivities,otherinvestingactivitiesnet,"Other Investing Activities, net",+,debit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-250000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-250000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-2124000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,netcashfromcontinuingfinancingactivities,issuanceofdebt,Issuance of Debt,+,debit,usd,1000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,netcashfromcontinuingfinancingactivities,issuanceofpreferredequity,Issuance of Preferred Equity,+,debit,usd,31782000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,29659000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,29659000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,22826000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,,cashinterestpaid,Cash Interest Paid,=,,usd,499000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 16:34:05+00:00,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-21426000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 16:34:05+00:00,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-21426000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 16:34:05+00:00,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,488000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 16:34:05+00:00,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,1098000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 16:34:05+00:00,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,9299000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 16:34:05+00:00,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-10565000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 16:34:05+00:00,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-21106000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 16:34:05+00:00,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-21106000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 16:34:05+00:00,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-985000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 16:34:05+00:00,netcashfromcontinuinginvestingactivities,otherinvestingactivitiesnet,"Other Investing Activities, net",+,debit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 16:34:05+00:00,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-910000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 16:34:05+00:00,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-910000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 16:34:05+00:00,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-2044000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 16:34:05+00:00,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-1438000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 16:34:05+00:00,netcashfromcontinuingfinancingactivities,issuanceofdebt,Issuance of Debt,+,debit,usd,6750000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 16:34:05+00:00,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,102672000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 16:34:05+00:00,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,15000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 16:34:05+00:00,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,105955000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 16:34:05+00:00,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,105955000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 16:34:05+00:00,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,83939000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 16:34:05+00:00,,cashinterestpaid,Cash Interest Paid,=,,usd,372000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13302000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13302000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,531000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,123000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,1397000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-903000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-12154000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-12154000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-2433000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-2433000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-2433000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-2128000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,131882000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,288000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,130042000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,130042000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,115455000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,,,cashinterestpaid,Cash Interest Paid,=,,usd,324000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13977000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13977000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,542000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,125000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,2045000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-1426000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-12691000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-12691000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-2026000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-2026000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-2026000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-2204000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,,netcashfromcontinuingfinancingactivities,issuanceofdebt,Issuance of Debt,+,debit,usd,131882000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,-131882000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,1099000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-1105000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-1105000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-15822000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,,,cashinterestpaid,Cash Interest Paid,=,,usd,275000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-15402000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-15402000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,531000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,44000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,2370000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-569000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-13026000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-13026000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-1801000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,0.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,0.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,netcashfromcontinuinginvestingactivities,otherinvestingactivitiesnet,"Other Investing Activities, net",+,debit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-1726000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-1726000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-2736000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,0.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,173000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-2563000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-2563000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-17315000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,,cashinterestpaid,Cash Interest Paid,=,,usd,110000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16805000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16805000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,544000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,128000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,2436000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,1211000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-12486000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-12486000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-491000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-53076000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-53567000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-53567000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-872000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,9625000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,8753000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,8753000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-57300000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,,,cashinterestpaid,Cash Interest Paid,=,,usd,190000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19175000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19175000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,511000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,236000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,2703000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,2019000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-13706000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-13706000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-557000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-1011000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-1568000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-1568000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-812000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,10154000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,9000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,9351000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,9351000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-5923000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,,,cashinterestpaid,Cash Interest Paid,=,,usd,264000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-22118000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-22118000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,409000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,193000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,5178000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-137000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-16475000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-16451000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-479000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,1000000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuinginvestingactivities,otherinvestingactivitiesnet,"Other Investing Activities, net",+,debit,usd,-75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,446000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,446000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-830000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuingfinancingactivities,issuanceofdebt,Issuance of Debt,+,debit,usd,126230000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,-133000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,1784000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,127051000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,127051000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,111046000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,,cashinterestpaid,Cash Interest Paid,=,,usd,238000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19888000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19888000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,344000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,456000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,3103000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,305000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-15680000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-15680000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-690000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-159754000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,16050000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-144394000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-144394000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-851000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-37000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,0.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,285000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-603000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-603000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-160677000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,,cashinterestpaid,Cash Interest Paid,=,,usd,203000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-24602000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-24602000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,355000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,330000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,7720000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-133000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-16330000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-16330000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-304000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuinginvestingactivities,acquisitions,Acquisitions,+,debit,usd,-1800000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-1000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,31000000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,28895000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,28895000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-874000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-145000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,312000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-707000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-707000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,11858000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,,,cashinterestpaid,Cash Interest Paid,=,,usd,181000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-17978000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-17978000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,369000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,243000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,3020000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-3000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-14349000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-14349000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-158000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,1000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,93000000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,92843000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,92843000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-897000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-61000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,294000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-664000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-664000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,77830000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,,,cashinterestpaid,Cash Interest Paid,=,,usd,158000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-26832000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-26832000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,377000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,183000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,10223000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,2592000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-13457000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-13468000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-518000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-120927000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuinginvestingactivities,saleofplantpropertyandequipment,"Sale of Property, Plant & Equipment",+,debit,usd,2000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,68600000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-52843000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-52843000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-919000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,251000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-668000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-668000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-66979000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,,cashinterestpaid,Cash Interest Paid,=,,usd,134000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-27156000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-27156000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,357000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,194000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,3298000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,2115000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-21192000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-21192000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-296000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-36028000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netcashfromcontinuinginvestingactivities,saleofplantpropertyandequipment,"Sale of Property, Plant & Equipment",+,debit,usd,0.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,7750000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-28574000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-28574000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-944000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-205000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,26217000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,-67000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,25001000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,25001000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-24765000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,,cashinterestpaid,Cash Interest Paid,=,,usd,110000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-26873000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-26873000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,365000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,132000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,3682000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-1596000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-24290000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-24290000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-1211000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuinginvestingactivities,acquisitions,Acquisitions,+,debit,usd,-100000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,37905000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,36594000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,36594000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-898000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-62000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,2883000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,1231000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,3154000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,3154000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,15458000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,,,cashinterestpaid,Cash Interest Paid,=,,usd,86000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-30651000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-30651000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,374000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,56000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,3231000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,5526000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-21464000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-21464000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-530000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,15000000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,14470000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,14470000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-885000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-174000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,9660000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,522000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,9123000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,9123000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,2129000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,,,cashinterestpaid,Cash Interest Paid,=,,usd,63000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-35907000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-35907000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,372000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,28000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,6713000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,398000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-28396000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-28396000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-488000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,96790000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,96302000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,96302000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-909000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-203000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingfinancingactivities,issuanceofdebt,Issuance of Debt,+,debit,usd,157468000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,2310000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,158666000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,158666000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,226572000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,,cashinterestpaid,Cash Interest Paid,=,,usd,40000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-35037000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-35037000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,390000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,-255000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,29027000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-5269000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-11144000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-11144000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-1068000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-199265000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netcashfromcontinuinginvestingactivities,saleofplantpropertyandequipment,"Sale of Property, Plant & Equipment",+,debit,usd,15000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,0.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-200318000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-200318000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-932000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-241000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,0.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,-1049000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-2222000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-2222000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-213684000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,,cashincometaxespaid,Cash Income Taxes Paid,=,,usd,0.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-34081000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-34081000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,417000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,-355000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,3686000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-6224000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-36557000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-36557000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-1267000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuinginvestingactivities,acquisitions,Acquisitions,+,debit,usd,-100000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-12932000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuinginvestingactivities,saleofplantpropertyandequipment,"Sale of Property, Plant & Equipment",+,debit,usd,131000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,18000000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,3832000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,3832000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-125000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,3070000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,2945000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,2945000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-29780000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-32834000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-32834000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,444000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,-294000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,165000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,7115000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-25404000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-25404000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-3032000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuinginvestingactivities,saleofplantpropertyandequipment,"Sale of Property, Plant & Equipment",+,debit,usd,1391000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,32000000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,30359000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,30359000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,895000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,895000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,895000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,5850000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-40616000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-40616000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,475000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,-199000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,33376000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-24177000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-31141000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-31141000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-1624000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-102714000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuinginvestingactivities,saleofplantpropertyandequipment,"Sale of Property, Plant & Equipment",+,debit,usd,4000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,163435000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,59101000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,59101000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,164000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,164000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,164000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,28124000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,,cashinterestpaid,Cash Interest Paid,=,,usd,16000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-35304000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-35304000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,628000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,-649000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,3862000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,20049000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-11414000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-11414000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-1084000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netcashfromcontinuinginvestingactivities,acquisitions,Acquisitions,+,debit,usd,0.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-127357000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,25000000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-103441000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-103441000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,0.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-201000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netcashfromcontinuingfinancingactivities,issuanceofdebt,Issuance of Debt,+,debit,usd,0.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,108100000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,-1031000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,106868000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,106868000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-7987000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-37390000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-37390000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,790000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,-832000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,4476000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,3666000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-29290000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-29290000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-382000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-37613000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuinginvestingactivities,saleofplantpropertyandequipment,"Sale of Property, Plant & Equipment",+,debit,usd,7000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,92000000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,54012000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,54012000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-320000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,363000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,43000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,43000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,24765000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,,,cashincometaxespaid,Cash Income Taxes Paid,=,,usd,3000000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-41406000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-41406000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,734000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,-734000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,9120000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,340000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-31946000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-31949000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-1484000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-63598000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,66000000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,918000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,918000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,-81000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-81000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-81000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-31112000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-45329000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-45329000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,757000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,-422000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,5132000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,6351000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-33511000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-33508000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-288000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-102794000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuinginvestingactivities,saleofplantpropertyandequipment,"Sale of Property, Plant & Equipment",+,debit,usd,1000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,134000000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,30919000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,30919000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-221000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingfinancingactivities,issuanceofdebt,Issuance of Debt,+,debit,usd,211970000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,-97230000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,308000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,114827000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,114827000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,112238000.0
